Condition: Alzheimer Disease · Mild Cognitive Impairment · Metabolic Syndrome · Sponsor: Rutgers, The State University of New Jersey
The investigators propose a proof of concept RCT (randomized clinical trial), testing the efficacy of intranasal insulin (INI) with semaglutide, a combination therapy with strong biological plausibility to benefit impaired cognition through vascular mechanisms, in older adults with MetS (metabolic syndrome) and MCI (Mild Cognitive Impairment), who are enriched for cerebrovascular disease and at high dementia risk. The study will focus on cognitive and biological outcomes, allowing identification of relevant mechanisms.
This description comes directly from the study's public registry record.
Iscka Yore · +972-35307262 · Iscka.Yore@sheba.health.gov.il
Tal Niv · +972-35305406 · Tal.Niv@sheba.health.gov.il
Always discuss trial participation with your own doctor first.
| Joseph Sagol Neuroscience center, Sheba Medical Center | Ramat Gan, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06072963